Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 20-F: Registration statement / Annual report / Transition report
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-LONG FOCUS CAPITAL MANAGEMENT, LLC(6.3%),JOHN B. HELMERS(6.3%), etc.
Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-PFIZER INC.(3.89%),Pfizer OTC B. V. N/A(3.89%)
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Baillie Gifford & Co (Scottish partnership)(3.06%)
Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-AstraZeneca Holdings B.V.(22.4%),AstraZeneca PLC(22.4%)
Cellectis | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]
Cellectis | SC 13D/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Caisse des Dépôts(9.7%),Bpifrance Participations S.A.(8.2%), etc.
Cellectis | SC 13D: Statement of acquisition of beneficial ownership by individuals-AstraZeneca Holdings B.V.(22.4%),AstraZeneca PLC(22.4%)
Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)
Cellectis | 6-K: Report of foreign private issuer (related to financial reporting)
No Data